Dear fellow Shareholders

The Offer

On behalf of the Board of TruScreen Group Limited (TruScreen), I am pleased to offer you an opportunity to participate in a Share Purchase Plan (SPP), under which you can apply for a maximum of $50,000 (A$45,000) of Shares in TruScreen at the lower of:

1. NZ$0.022 (A$0.02) per Share (representing a 24.1% discount to the five day VWAP during the last five trading days prior to the Record Date); or
2. a 2.5% discount to the five-day VWAP during the last five trading days before and including the Closing Date.

Share Options

Subject to shareholder approval in a general meeting, to be held shortly following the close of the SPP, shareholders who participate in the SPP will also receive a free unlisted option based on 1 unlisted option for every SPP New Share (Share Option). The expiry date of the Share Options is 12 months from the date of issue of the SPP New Share with an exercise price of NZ$0.022 (A$0.02) per Share Option. Share Options may be exercised at any time but Shares issued pursuant to the exercise of Share Options will only be allotted on the last Australasian Business Day of the month in which they are exercised.

The Share Options will be offered by TruScreen to shareholders in Australia pursuant to a Prospectus that will be provided to Eligible Shareholders with a registered address in Australia. A copy of the Prospectus is also available here. Eligible Shareholders in Australia should consider the Prospectus in deciding whether to apply for the Share Options, and if they wish to do so, they must complete the application form that will be in or will accompany the Prospectus.

If shareholder approval for the grant of the Share Options is not obtained, the offer and issue of Shares under the SPP pursuant to this Booklet may proceed. However, the grant of the Share Options may not occur. In these circumstances, participants in the SPP may receive New Shares under the SPP but not Share Options.

Recent highlights

TruScreen has continued to make significant progress in the financial year to 31 March 2025.

Highlights include:

• Memorandum of Understanding signed with Hangzhou Dalton Bioscience to expand its HPV product offerings
• Launch of a 260,000 women cervical cancer screening program at Ho Chi Minh City Public Health Association
• Indonesian distributor appointed with commercial sales commenced in a significant addressable market
• Uzbekistan product registration in progress to enable the evaluation of TruScreen for a national cervical cancer screening program
• Inclusion in World Health Organisation and UNITAID screening guidelines
• Invitation by World Health Organisation to present to and participate in an important meeting in Edinburgh to discuss the use of AI and digital technology to lower the incidence and mortality from cervical cancer
• Inclusion in Chinese Obstetricians and Gynecologists Association (COGA) Blue Book guideline and China Society for Colposcopy and Cervical Pathology (CSCCP) guideline
• Cofepris approval for use in Mexico Public Health system
• Agreement on validation protocol for additional public screening programs in Zimbabwe · Appraisal by Baylor foundation (https://baylorfoundationeswatini.org/) for a public screening program in Eswatini
• Saudi Arabia study published with sensitivity 83.3% and specificity 95% compared with Pap smear of 66.7% and 98.2% respectively
• TruScreen ranked in top 6 health care companies in having a significant impact to global women’s health by Health Startups 2024 report
• Appointment of distributor for India, the world’s second most populous country

China remains TruScreen's key market with revenue in line with the prior year. Recent improvements in Single Use Sensor (SUS) usage/pull through (which increased 30% year on year) and an expansion into new provinces will build on this strong base in FY2026. Product re-validation in Zimbabwe pushed expected Q4FY2025 revenue into FY2026.

Intended use of funds

The funds raised from the SPP will be applied towards:

• Growing and increasing TruScreen’s presence in the Chinese market;
• Distribution of Dalton Bio IVD HPV DNA products;
• Executing public cervical cancer screening programs in Vietnam, Zimbabwe and Uzbekistan;
• Continued development of the growing public cervical cancer screening sales channel with key NGOs and Ministries of Health;
• Development of Indonesian and ASEAN markets;
• Development of Indian market; and
• Providing additional working capital.

Directors Intention to participate in the SPP

The directors who hold shares in TruScreen at the Record Date of 28th May 2025 have advised the Company of their intention to participate in the SPP, as outlined in the prospectus.

Further details about the SPP and the terms and conditions are set out in this Booklet and the accompanying Application Form. You should read these documents carefully and seek professional advice if you have any queries about making an investment decision. Further information about TruScreen can be found on our web site truscreen.com

The SPP closes at 7:00pm New Zealand time on Monday, 23 June 2025. If you wish to participate in this SPP, please ensure that you complete an online application or return the completed application form contained in this booklet and payment to MUFG Corporate Markets (formerly Link Market Services) by the Closing Date.

On behalf of the Board, I thank you for your ongoing support of TruScreen Group Limited.

Yours sincerely,

Tony Ho
Chairman